Phenomics and Genomics of Clozapine Pharmacotherapy

NCT ID: NCT03253367

Last Updated: 2020-03-05

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 2500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-01-19
• Study Completion Date: 2021-12-31

Brief Summary

A burgeoning body of research has pointed to increased efficacy of clozapine (CLZ) over other antipsychotics in schizophrenia (SCZ). On the other hand, safety concerns likely cause underutilization across a range of European and other nations. The lack of data available to predict efficacy and adverse drug reactions (ADRs) of CLZ further contributes to underprescription rates in these countries. Here, we hypothesize that (epi)genetic and non-genetic factors aid to help predict treatment outcome (efficacy + ADRs) to CLZ. We furthermore posit that such prediction will result in enhanced quality of life of both patients and family members. Our primary objective is to predict CLZ treatment outcome based on phenotypic and genetic data obtained through the current design. The first secondary objective is to investigate which methylation levels/patterns are correlated with CLZ treatment outcome. The second secondary objective is to aid in the further elucidation of the genetic architecture of SCZ and any possible differences between 'regular' SCZ patients and those on CLZ, who are generally more severely ill. We thus intend to cover two currently unmet needs using a precision medicine approach: the lack of knowledge about determinants of treatment response to CLZ and the lack of insight into neurobiological differences between 'regular' SCZ and relatively treatment resistant subjects (CLZ users). The prime analysis will be a common variant hypothesis-generating genotyping endeavor investigating treatment response to CLZ. Additional analyses include whole-genome methylation and gene expression analyses and analyses of non-genetic determinants of response. We will include 2,500 CLZ treated patients for our discovery cohort, which is in line with previous whole-genome pharmacogenomics studies and our power calculations. We will replicate any genome-wide loci using our prospectively collected cohort of new users (N=59). Potential yields include a publicly available prediction tool to help identify patients responsive to CLZ in early disease stages and prevent harmful effects. In addition, common variant analyses compounded by pathway analyses may help elucidate the mechanisms of action of CLZ. We ask for broad informed consent from participants ensuring rich, longitudinal phenotypic and genotypic data resources for both currently planned and future analyses, allowing e.g. next-generation sequencing focused on both CLZ and SCZ disease genetics (e.g. in large consortia). We plan to also generate polygenic risk scores (PRS) of CLZ efficacy and use those to identify other diseases or patients for which CLZ may be helpful, e.g. schizoaffective disorder patients who are sometimes first treated with mood stabilizers. Last, evidence hints that disparaging genetic loci influence efficacy to different antipsychotics. Adding genetic data from our cohort to existing datasets of response to other antipsychotics may help identify such loci. Finally, comparison studies with non-CLZ using patients suffering from SCZ may deepen the understanding of biological mechanisms underlying treatment resistance (or: a relatively severe course of illness).The results of this genetic part of the study will be combined with the results from our other research protocol 'Phenomics and genomic of clozapine pharmacotherapy - New Users'.The overarching goal of both projects is to create a prediction model for clozapine outcome (response (and side effects). This model includes genetic, epigenetic and clinical data.

Detailed Description

Rationale Clozapine (CLZ) is generally prescribed if at least two trials of antipsychotic agents have not led to satisfactory clinical improvement, thereby implying that patients on CLZ generally suffer from more severe and/or persistent symptoms than patients suffering from schizophrenia spectrum disorders (SCZ) on other antipsychotic agents. Unraveling the (functional) genetic variation underlying this severe SCZ phenotype therefore has the potential to deepen our understanding of the biological underpinnings of SCZ beyond the boundaries of DSM-based consensus criteria. Such knowledge in turn has the potential to shape future pharmacotherapeutic research. The investigators here hypothesize that targeting this phenotype in genome-wide association studies and next-generation sequencing studies will signal genetic risk loci implicated in this severe SCZ phenotype. In the future, this may lead to early detection of severe SCZ, which in turn will enable tailoring of pharmacotherapeutic strategies to such SCZ subtypes. The results of this genetic part of the study will be combined with the results from our other research protocol ('Phenomics and genomic of clozapine pharmacotherapy - New Users').The overarching goal of both projects is to create a prediction model for clozapine outcome (response (and side effects). This model includes genetic, epigenetic and clinical data.

Objectives

Primary:

1) To predict CLZ efficacy and ADRs (=treatment outcome) based on phenotypic and genetic data obtained in this study.

Secondary:

1. To investigate which non-genetic factors, methylation and gene expression levels/patterns predict treatment outcome after initiating CLZ;

2. As the genetic architecture of SCZ has not been fully elucidated, the current project will aid in the further elucidation of the genetic architecture of SCZ and any possible differences between 'regular' SCZ patients (those not considered treatment resistant) and those on CLZ (considered generally to be a more homogeneous and severe group).

Study design This is a mostly cross-sectional study, in which both phenotypic and genotypic data are gathered from this study population that currently uses CLZ or has used CLZ in the past. A genome-wide association study (GWAS) will be performed to reveal possible differences in genetic architecture between patients who use or have used CLZ and the broad schizophrenia phenotype on the one hand and between those who use or have used CLZ and healthy controls on the other. Targeted next-generation sequencing may be used to follow-up possible positive associations. The genetic data will be used to analyse which genetic variants are associated with CLZ response and/or side effects.

Study population The investigators will include 2,500 patients diagnosed with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS (together referred to as SCZ) >18 years of age who are currently on CLZ treatment or have used CLZ in the past. Publicly available Psychiatric Genomics Consortium (PGC) GWAS data will be used for comparisons with the broad schizophrenia phenotype group. For the purpose of the case-control comparison, the 2,500 subjects who use or have used CLZ will be age and sex-matched to 30,000 healthy control subjects for whom genotype data are available in-house.

Intervention No intervention will be applied.

Main study parameters/endpoints

1. To assess whether the genetic architecture of this severe SCZ phenotype differs from the broad DSM-based SCZ phenotype.

2. To predict clozapine response and side effects based on phenotypic and genetic data obtained in this study.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness Almost all patients on CLZ regularly have their blood drawn for routine white blood cell counts and/or CLZ blood level assessments. The investigators anticipate that the majority of the study population will consist of such patients as white blood cell monitoring is strictly enforced in clinical practice for this patient group. For these patients, no additional risks will be attached to the study, as the blood necessary for DNA extraction for the current study will be drawn during these routinely performed venipunctures. Time investment will also be low as the patients will only undergo a 10-minute interview. A minority of patients on CLZ does not have their blood routinely monitored and neither do patients who have used CLZ in the past. These subjects will be asked to allow a single blood draw. A venipuncture entails the risk of a hematoma (blood leaving the vessel). The investigators aim to minimize this risk by only allowing experienced personnel to draw blood and in the event of deeply located or thin veins request central lab personnel to perform the venipuncture. Although a hematoma resulting from a traumatic puncture imposes an esthetical burden on the subject, no serious health risks are involved.

Conditions

Schizophrenia Spectrum and Other Psychotic Disorders

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

Current/former clozapine users

This group has only one visit.

Blood is obtained, mostly during routine venipuncture

Intervention Type: OTHER

New clozapine users

This group will be followed for 6 months prospectively.

Blood is obtained, mostly during routine venipuncture

Intervention Type: OTHER

Interventions

Blood is obtained, mostly during routine venipuncture

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• he/she currently uses CLZ or he/she has used CLZ in the past/will use CLZ
• he/she has received a diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS.
• his/her age must be ≥18 years old
• he/she must be able to speak and read the language of the Informed Consent (differs per country)
• he/she must be mentally competent and have decisional capacity with regard to a decision to participate in the current study

Exclusion Criteria

• admission to a psychiatric unit involuntarily (not all countries)
• a history of Parkinson's disease

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jurjen Luykx

OTHER

Sponsor Role: lead

Responsible Party

Jurjen Luykx

Sponsor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Medical University Innsbruck

Innsbruck, , Austria

Site Status: RECRUITING

Niuvanniemen hospital

Kuopio, , Finland

Site Status: RECRUITING

LMU Munich

München, Munich, Germany

Site Status: RECRUITING

Charité Universitätsmedizin Berlin

Berlin, , Germany

Site Status: RECRUITING

Vincent van Gogh Institute

Venray, Limburg, Netherlands

Site Status: WITHDRAWN

Reinier van Arkel

's-Hertogenbosch, North Brabant, Netherlands

Site Status: RECRUITING

GGZ-NHN

Heerhugowaard, North Holland, Netherlands

Site Status: TERMINATED

GGZ Rivierduinen

Leiden, Oegstgeest, Netherlands

Site Status: ENROLLING_BY_INVITATION

Yulius

Barendrecht, South Holland, Netherlands

Site Status: TERMINATED

UMC Utrecht

Utrecht, , Netherlands

Site Status: RECRUITING

Altrecht

Utrecht, , Netherlands

Site Status: TERMINATED

Countries

Austria; Finland; Germany; Netherlands

Central Contacts

Marte van der Horst, Drs.

Role: CONTACT

mzvanderhorst@gmail.com

0887551460 ext. +31

Jurjen Luykx, PhD

Role: CONTACT

j.luykx@umcutrecht.nl

0887568638 ext. +31

Facility Contacts

Monika Edlinger, MD

Role: primary

monika.edlinger@i-med.ac.at

Jari Tiihonen, Prof.

Role: primary

Alkomiet Hasan, MD, PhD

Role: primary

Stefanie Schreiter, MD

Role: primary

stefanie.schreiter@charite.de

004930450517009

Stefan Gutwinski, MD

Role: backup

stefan.gutwinski@charite.de

004930450517009

Koen Grootens, MD

Role: primary

Marte van der Horst, Drs.

Role: primary

c.pfeifer@umcutrecht.nl

0887551460 ext. +31

Related Links

http://www.clozinstudy.com

Website CLOZIN study

Other Identifiers

ABR: 52726 & 52728

Identifier Type: -

Identifier Source: org_study_id